Clinical trial NCT02217644: Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers
Official title: Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers (Dose Range: 0.1 mg - 1500 mg). A Singleblind (Within Dose Groups), Randomised, Placebo-controlled Within Dose Groups, Single Rising Dose Phase I Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-08-15
Enrollment: 80
Sex: MALE
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: * Investigation of safety and tolerability of BI 653048 H3PO4 following the administration of single rising doses of an aqueous solution in healthy male subjects
* Pharmacokinetic and pharmacodynamic characteristics of BI 653048, including the investigation of dose proportionality
* Investigation of relative bioavailability of capsules versus aqueous solution


Eligibility criteria: Inclusion Criteria:

* Healthy males according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests
* Age ≥21 years and ≤50 years
* Body Mass Index (BMI) ≥18.5 kg/m2 and BMI ≤29.9 kg/m2
* Signed and dated written informed consent prior to admission to the trial in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion Criteria:

* Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
* Any evidence of a clinically relevant concomitant disease
* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
* Surgery of the gastrointestinal tract (except appendectomy)
* Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
* History of relevant orthostatic hypotension, fainting spells or blackouts
* Chronic or relevant acute infections
* History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
* Intake of drugs with a long half-life (\>24 h) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
* Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial
* Participation in another trial with an investigational drug within 2 months prior to administration or during the trial
* Smoker (\>10 cigarettes or \>3 cigars or \>3 pipes/day)
* Inability to refrain from smoking on trial days
* Alcohol abuse (more than 60 g/day)
* Drug abuse
* Blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)
* Excessive physical activities (within 1 week prior to administration or during the trial)
* Any laboratory value outside the reference range that was of clinical relevance
* Inability to comply with dietary regimen of trial site
* A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval \>450 ms)
* A history of additional risk factors for Torsades des Pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)
* Not willing to use adequate contraception (condom use plus another form of contraception e.g., spermicide, oral contraceptive taken by female partner, sterilisation, intrauterine device) during the whole trial period from the time of the first intake of trial drug until 3 months after the last intake

Primary outcomes:
measure: Number of patients with clinically significant findings in vital signs
timeFrame: up to 10 days after drug administration
measure: Number of patients with clinically significant findings in ECG
timeFrame: up to 10 days after drug administration
measure: Number of patients with clinically significant findings in laboratory tests
timeFrame: up to 10 days after drug administration
measure: Number of patients with adverse events
timeFrame: up to 10 days after drug administration
measure: Assessment of tolerability performed by the investigator on a four-point scale
timeFrame: up to 10 days after drug administration
Secondary outcomes:
measure: Cmax (maximum measured concentration of the analyte in plasma)
timeFrame: up to 72 hours after drug administration
measure: tmax (time from dosing to maximum measured concentration)
timeFrame: up to 72 hours after drug administration
measure: AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)
timeFrame: up to 72 hours after drug administration
measure: %AUCtz-∞ (the percentage of the AUC0-∞ that is obtained by extrapolation)
timeFrame: up to 72 hours after drug administration
measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point)
timeFrame: up to 72 hours after drug administration
measure: AUCt1-t2 (Area under the concentration-time curve of the analyte in plasma over the time interval t1 to t2)
timeFrame: up to 72 hours after drug administration
measure: λz (terminal rate constant in plasma)
timeFrame: up to 72 hours after drug administration
measure: t1/2 (terminal half-life of the analyte in plasma)
timeFrame: up to 72 hours after drug administration
measure: MRTp.o. (mean residence time of the analyte in the body after oral administration)
timeFrame: up to 72 hours after drug administration
measure: CL/F (total/apparent clearance of the analyte in plasma after extravascular administration)
timeFrame: up to 72 hours after drug administration
measure: Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)
timeFrame: up to 72 hours after drug administration
measure: Aet1-t2 (amount of analyte eliminated in urine from the time point t1 to time point t2)
timeFrame: up to 48 hours after drug administration
measure: fet1-t2 (fraction of analyte eliminated in urine from time point t1 to time point t2)
timeFrame: up to 48 hours after drug administration
measure: CLR,t1-t2 (renal clearance of the analyte from the time point t1 until the time point t2)
timeFrame: up to 48 hours after drug administration
measure: Dose-normalised Cmax
timeFrame: up to 72 hours after drug administration
measure: Dose-normalized AUC0-∞
timeFrame: up to 72 hours after drug administration
measure: Emax (maximum measured concentration of the biomarker in blood or serum)
timeFrame: up to 72 hours after drug administration
measure: Emin (minimum measured concentration of the biomarker in blood or serum)
timeFrame: up to 72 hours after drug administration
measure: Tmin (time from dosing to minimum measured concentration of the biomarker)
timeFrame: up to 72 hours after drug administration
measure: Tmax (time from dosing to maximum measured concentration of the biomarker)
timeFrame: up to 72 hours after drug administration
measure: AUECt1-t2 (area under the concentration-time curve of the biomarker in the blood over the time interval from t1 to t2)
timeFrame: up to 72 hours after drug administration
measure: AUECbelow_base (area under the baseline corrected concentration-time curve of the biomarker)
timeFrame: up to 72 hours after drug administration
measure: AUECabove_base (area above the baseline corrected concentration-time curve of the biomarker)
timeFrame: up to 72 hours after drug administration
measure: Expression of glucocorticoid responsive genes
timeFrame: up to 72 hours after drug administration
Other outcomes:
Locations:
Study officials:
References:
citation: Harcken C, Scholl P, Nabozny G, Thomson D, Bianchi D. Clinical profile of the functionally selective glucocorticoid receptor agonist BI 653048 in healthy male subjects. Expert Opin Investig Drugs. 2019 May;28(5):489-496. doi: 10.1080/13543784.2019.1599859. Epub 2019 Apr 9.